Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.

Saved in:
Bibliographic Details
Title: Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.
Authors: Weiss, Laurence1,2,3 laurence.weiss@egp.aphp.fr, Chevalier, Mathieu F.3,4, Assoumou, Lambert5,6, Paul, Jean-Louis7,8, Alhenc-Gelas, Martine9, Didier, Céline3, Taibi, Saïd5,6, Manea, Elena-Maria1, Campa, Pauline8, Girard, Pierre-Marie5,6,10, Costagliola, Dominique5,6
Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 4/1/2016, Vol. 71 Issue 4, p390-398. 9p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first